Abstract | A revolution in the analysis of seven transmembrane domain (7TM) receptors has provided detailed information about how these physiologically important signalling proteins interact with extracellular cues. However, it has proved much more challenging to understand how 7TM receptors convey information to their principal intracellular targets: heterotrimeric G proteins, G protein-coupled receptor kinases and arrestins. Recent structures now suggest a common mechanism that enables these structurally diverse cytoplasmic proteins to 'hitch a ride' on hundreds of different activated 7TM receptors in order to instigate physiological change.
Seven transmembrane domain (7TM) receptors are integ ral membrane proteins capable of binding an extraordinary variety of ligands (FIG. 1) and relaying this event across lipid bilayers to a much smaller set of signalling proteins inside the cell. Because many 7TM receptors transduce signals to heterotrimeric G proteins, they are commonly referred to as G protein-coupled receptors (GPCRs). However, the term is misleading, because these receptors also interact with at least two other protein families in an activation-dependent manner, the GPCR kinases (GRKs) and arrestins, which instigate cellular responses distinct from those of heterotrimeric G proteins 1, 2 
. The physiological importance of the 7TM receptor family is evidenced by its great expansion in the genomes of complex eukaryotes, with typic ally around 1,000 different members in mammalian species (humans have approximately 800) 3 . 7TM receptors control strikingly diverse physiological phenomena, ranging from glucose metabolism to blood pressure regulation to neurotransmission. A large proportion of 7TM receptors are involved in sensory perception, wherein individual receptors have evolved to recognize specific classes of odorants, tastants or wavelengths of light. Most mammalian 7TM receptors can be classified by sequence homology in their transmembrane spans into one of five families 3, 4 : glutamate, rhodopsin, adhesion, frizzled and secretin (FIG. 1) . The rhodopsin family (also known as class A) is the largest and most diverse in terms of its ligand-binding repertoire and is further subdivided into α-, β-, γ-and δ-subfamilies. The α-subfamily contains receptors responsive to most of the biogenic amines (for example, adrenaline and acetylcholine) and is the best characterized functionally and structurally 5 . The other rhodopsin subfamilies are primarily peptide or odorant receptors. Although signalling by all five 7TM receptor families has been shown to be dependent on hetero trimeric G proteins, direct coupling still remains to be definitively shown for the frizzled family 6 . The ability of their extracellular domains to interact with small molecules, and the profound physiological consequences of these interactions, have rendered 7TM receptors the targets of a substantial proportion of currently prescribed drugs 7 . Understanding the molecular basis of their function is thus an important step towards understanding human physiology and disease.
This Review discusses recent insights provided by X-ray crystallography and complementary techniques into how activated 7TM receptors interact with and transmit extracellular signals to their cytoplasmic signalling partners. Focusing on the interactions with heterotrimeric G proteins and arrestins, the Review presents a common mechanism by which intracellular signalling components 'hitch a ride' on activated receptors by extending a structural 'thumb' that interacts with an exposed pocket in the cytoplasmic domain of the receptor. In each case, receptor engagement stabil izes an allosteric change in the 'hitchhiking' protein that instigates intracellular signalling cascades.
Signalling by 7TM receptors
The most well-known function of 7TM receptors is to cata lyse the exchange of GDP bound to the heterotrimeric G protein α-subunit (Gα) for GTP. Subsequently, Gα-GTP dissociates from the heterotrimeric G protein βγ-subunits (Gβγ), and both components can then interact with downstream effector targets
. Hydrolysis of GTP on Gα returns the subunit to a state with high affinity for Gβγ, ultimately regenerating the Nature Reviews | Molecular Cell Biology 
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Transducin
The heterotrimeric G protein (also known as G t ) responsible for the propagation of visual signals from light-activated rhodopsin.
Homologous desensitization
The process by which receptors that recognize a specific agonist or signal become gradually resistant to further stimulation, often by downregulation of the number of receptors on the cell surface through endocytosis.
Clathrin-mediated endocytosis
A process by which membrane proteins are sequestered into distinct regions of the cell membrane, which are then internalized with the help of the protein clathrin to form intracellular vesicles.
Agonists
Molecules that promote a conformation (or an ensemble of conformations) of a receptor that is more capable of binding to and activating a downstream signalling protein.
Biased agonism
A phenomenon in which an agonist (known as a biased agonist) promotes interactions with one downstream signalling partner or cascade over another.
Inverse agonist
A molecule that reduces signalling by a receptor to a level below that observed in its basal, unliganded state.
inactive Gαβγ heterotrimer. A single activated receptor can turn over multiple hetero trimeric G protein complexes. For example, each photo-activated molecule of rhodopsin is thought to turn over hundreds of transducin (G t ) hetero trimers to instigate the visual response 8 . GRKs and arrestins also interact preferentially with activated 7TM receptors, and together they orchestrate receptor uncoupling from heterotrimeric G proteins and receptor internalization in a process called homo logous desensitiza tion 9 . GRKs phosphorylate most 7TM receptors at multi ple Ser and Thr residues, primarily in their extended carboxy-terminal tails or third intracellular loops 10 , which enhances the affinity of arrestins for receptors. Arrestin binding then blocks access of heterotrimeric G proteins 11 , targets the receptor for clathrin-mediated endocytosis 12, 13 and instigates unique signalling cascades, including those of MAP kinases 14 and Src 15 
Understanding the mechanisms by which agonists promote the activated state of a 7TM receptor could be considered the holy grail of modern molecular pharmacology. This quest has taken on new importance with the recent discovery that some agonists can preferentially promote recruitment of one cytoplasmic partner over another, and hence differentially modulate downstream signalling via the same receptor -a concept known as biased agonism or functional selectivity 16, 17 . For example, morphine, which functions at opioid receptors, not only provides pain relief (analgesia) but also causes constipation and dependency. However, these undesirable side-effects are reduced in mice lacking arrestin 3 (REF. 18 ). Thus, there is great interest in develop ing analgesics that activate G protein signalling without recruiting arrestin 3 (REF. 19 ). The simplest molecular explanation for the phenomenon of biased signalling is that some ligand-stabilized receptor conformations are more compatible with heterotrimeric G proteins than other signalling partners, and vice versa.
The 7TM receptor structural revolution Rhodopsin is an unusual member of the 7TM family in that it is covalently attached to a light-reactive ligand, 11-cis-retinal, which effectively functions as an inverse agonist that keeps basal signalling very low in the absence of light. Conformational stabilization of rhodopsin by 11-cis-retinal, along with its natural abundance in vertebrate retinas, facilitated its structural characterization long before that of other, more conformationally labile 7TM receptors 20 (see Supplementary information S1 ( figure)). In 1993, rhodopsin isolated from bovine and frog retinas was crystallized in thin, ordered sheets, and then analysed by electron crystallography to reveal electron density for each of the seven helical transmembrane spans (referred to as TM1-TM7), which confirmed the predicted topology of a 7TM receptor 21, 22 . It took seven more years to obtain a three-dimensional structure, which revealed the presence of a short eighth cytoplasmic helix (α8) that bears palmitoylation , and representative activating ligands are listed for each group. Odorant receptors (388 in number) are included in the rhodopsin family. Not shown are the taste 2 receptors (25 in number), whose transmembrane domains most closely resemble those of the frizzled family, but which lack analogous extracellular domains (ECDs). Glutamate family receptors dimerize through their VFDs (Venus fly trap domains). The GAIN (GPCR autoproteolysis-inducing) domain of adhesion receptors has autoproteolytic activity that cleaves its extracellular domain, such that the mature protein exists as two non-covalently associated subunits. Blue shapes represent the mode by which agonists interact with the extracellular regions of each receptor family. The frizzled ligand is covalently modified by a palmitoyl group (jagged line), which forms part of the interface with the Cys-rich domain (CRD). sites in rhodopsin and many other 7TM receptors 23 . Another seven years passed before the atomic structure of another 7TM receptor, the hormone-responsive β 2 -adrenergic receptor (β 2 AR), was reported 24, 25 . At the time of submission, the trans membrane domains of 34 unique 7TM receptors have been characterized, described by 138 unique entries in the Protein Data Bank (see Supplementary information S1,S2 ( figure,  table) ). There are now representative crystal structures for the transmembrane domains of every 7TM receptor family except the adhesion class, probably because the functional analysis of this family lags behind the others. All confirm the same underlying heptahelical fold but exhibit great structural diversity in their extra cellular ligand-binding pockets, as would befit the great variety of ligands that interact with 7TM receptors 5 (FIG. 1) . Some technological advances that helped to catalyse the expansion in the number of 7TM receptor crystal structures are summarized in BOX 2. From structure to function What can we learn from all these new 7TM receptor structures about how they interact with and activate their downstream partners? To begin addressing this question mechanistically, one ideally would compare structures of both active and inactive states, preferably from the same receptor. However, this is much more challenging than it sounds, in part because most receptors have only been resolved in complex with an inverse agonist or an antagonist -that is, in inactive (inhibited)
Box 1 | Interactions of 7TM receptors with downstream signalling partners
Seven transmembrane domain (7TM) receptors interact in an agonist-dependent manner (R* indicates an agonist-bound receptor) with at least three families of intracellular proteins: heterotrimeric G proteins, G protein-coupled receptor kinases (GRKs) and arrestins. In each case, the activated receptor, in collaboration with the local membrane environment, drives a conformational change in the signalling partner that instigates downstream signalling events. For heterotrimeric G proteins (see the figure, part a) , the exchange of bound GDP for GTP on the Gα subunit reorganizes a structural element known as switch II (red helix) in its Ras-like domain that interacts directly with effector enzymes, which include adenylyl cyclase, phospholipase Cβ (PLCβ), cGMP phosphodiesterase and Rho family guanine exchange factors (RhoGEFs). Nucleotide exchange also results in the dissociation of the Gβγ subunit from Gα, thereby enabling Gβγ to interact with its own signalling partners, including the regulation of G protein-coupled inwardly rectifying potassium (GIRK) channels, GRK 2 and 3, phosphoinositide 3-kinase-γ (PI3Kγ), phosphatidylinositol-3,4,5-trisphosphate-dependent RAC exchanger 1 protein (P-Rex1), PLCβ and PLCε. For GRKs (see the figure, part b) , the conformational change involves stabilization of the active conformation of its kinase domain, which uses ATP to phosphorylate multiple Ser and Thr residues not only on the bound receptor itself, but also on nearby proteins (including non-active receptors), in a process called high-gain phosphorylation, which inhibits nearby receptors from signalling in response to future agonist exposure 83 . 7TM receptor phosphorylation then facilitates arrestin binding to the receptor, which results in conformational changes in arrestin (see the figure, part c), including rearrangement of its polar core, a change in orientation of its N and C domains, and release of its carboxy-terminal tail. These changes provide binding sites for endocytic machinery on its C terminus and grant access to other signalling proteins, such as MAP kinases, on its N and C domains. The C domain has also been proposed to interact with the lipid bilayer in the receptor-bound state, but the importance of such an interaction is, as of now, unknown.
Nanobodies
Single-domain, ~15 kDa fragments produced from single heavy-chain antibodies found in cameloid species (for example, llamas and alpacas). They are now also generated by in vitro methodologies such as directed evolution.
states -or have had functionally important loops truncated or replaced by rigid domains to facilitate their crystallization
. Additionally, comparison is confounded by the fact that it is not always clear what is meant by an 'active' structure, because simple addition of agonist only increases the probability of achieving an active conformation. For example, crystal structures of β 1 AR, β 2 AR and the A 2A adenosine receptor (A 2A AR) were each determined in complex with an agonist, but their transmembrane domains seem to adopt inactive or intermediate conformations [26] [27] [28] [29] . This result could be a consequence of the protein engineering used to achieve the structures (thermostabilization in the case of β 1 AR or insertion of lysozyme in the third intracellular loops of β 2 AR and A 2A AR), or of the fact that, in the absence of cytoplasmic partners, agonist-bound receptors still frequently relax into inactive conformations 26 . Hereafter, this Review considers an 'active' conformation to be one that has been determined in complex with proteins that recognize the activated state of the receptor, such as hetero trimeric G proteins, arrestins and conformationally sensitive nanobodies [30] [31] [32] [33] . Notably, rhodopsin seems to be a special case, because its retinal-free form (opsin) can crystallize in what seems to be an activated configuration, whether or not all-trans-retinal (the lightactivated conformation of its chromophore) is bound 34 . This characteristic has enabled rhodopsin to be visualized in complex with peptide fragments derived from the Gα subunit of transducin (Gα t ) 35 and arrestin 1 (REF. 36 ). Of course, the most definitive examples of active 7TM receptors are those in complex with intact cytoplasmic targets, of which there are currently only two examples: β 2 AR in complex with the stimulatory Gα s βγ heterotrimer (referred to as G s ), and rhodopsin in complex with arrestin 1 (REFS 37, 38) . After a brief overview of how agonists influence the conformation of 7TM receptors, these two complexes will serve as the basis for discussing how activated receptors might generally interact with their intracellular partners to instigate intracellular signal transduction.
Agonist-induced conformational changes in 7TM receptors. Currently, structures representing inactive and active states of the same 7TM receptor are only available for rhodopsin, β 2 AR, the μ-opioid receptor and the M2 muscarinic receptor (FIG. 2) . In each case, the transmembrane domain of the receptor forms a twisted helical barrel with an up-and-down fold. A deep pocket or cavity in the extracellular end of each of the barrels features specific residues and/or surfaces that complement the chemical properties of their diverse ligands (FIGS 1, 2a) . Ligand binding promotes the generation of a shallower pocket on the cytoplasmic end of the receptor. This is achieved by a large motion of the ends of TM5 and, in particular, TM6 away from the transmembrane core, and usually an inward shift of the end of TM7 and the α8 helix (FIG. 2b) . This conformational change was first proposed on the basis of light-induced changes in the electron paramagnetic resonance of spin-labelled rhodopsin 39 
. Relative to the antagonist-bound conformation, the extracellular pocket can either expand, contract or remain essentially unchanged upon agonist binding (FIG. 2a) . In comparison, the cytoplasmic pockets of these receptors undergo dramatic but consistent changes to achieve their activated conformation (FIG. 2b) . In other words, 7TM receptors seem to function as 'allosteric funnels' , wherein diverse ligand-induced structural changes in the extracellular pocket trigger allosteric pathways that converge on specific transitions in the cytoplasmic domain. Experimental support for this model was recently provided by nuclear magnetic resonance (NMR) studies (BOX 3) of thermostabilized β 1 AR incorporated with 15 N-Val, in which the backbone conformation of specific amino acids in the cytoplasmic domain altered their environment in a unified way, indicating a common conformational change. The degree of change correlated strongly with the efficacy of the bound ligand 40 . Conformational transitions in 7TM receptors are facilitated by a loose network of water molecules and polar interactions inside the transmembrane barrel, which are thought to contribute to allosteric coupling between the extracellular and cytoplasmic pockets 41 . The binding of ions within these internal
Box 2 | Crystallographic technologies driving the 7TM receptor revolution
Successful structural analysis of hormone-responsive seven transmembrane domain (7TM) receptors required a deep understanding of which parts of the receptor were conformationally labile (for example, the carboxy-terminal tail and third cytoplasmic loop). These elements could then be either truncated and/or substituted with more rigid, crystallizable exogenous domains. For example, lysozyme has been used to replace the third cytoplasmic loop of some receptors 25 and was fused to the amino terminus of rhodopsin in the arrestin 1 complex 38 . Conformationally selective antibody fragments have been developed to stabilize specific receptor states and, like lysozyme, provide additional surface area for the formation of crystal contacts. For example, Nb80 is a cameloid nanobody specific for the active conformation of the β 2 -adrenergic receptor (β 2 AR), and it facilitates crystallization 30 as well as detection of active internalized receptors in cells 84 . Thermostabilization of 7TM receptors through mutagenesis has also been used to dampen conformational heterogeneity and improve expression. These and other biochemical breakthroughs have been extensively reviewed elsewhere 85, 86 . Advances in receptor engineering have been accompanied by parallel advances in X-ray diffraction data collection technologies developed at synchrotron sources. The General Medical Sciences and Cancer Institute Structural Biology Facility at the Advanced Photon Source (GM/CA) has been particularly successful, as it is responsible for and/or contributed to a large fraction of 7TM receptor structures currently deposited in the Protein Data Bank (see Supplementary information S1,S2 (figure, table)). They were the first to bring together raster scanning of samples, the use of an intense microbeam and stable software 87, 88 , which together facilitated data collection from small receptor crystals that are all but invisible when grown in lipid cubic phase 89 . An exciting new development is serial femtosecond crystallography (SFX) 90 , which involves microcrystals of receptors or receptor complexes grown in lipid cubic phase being passed through an X-ray free-electron laser in a stream with the consistency of toothpaste. When the laser hits a microcrystal, the crystal is obliterated but persists for long enough to emit a diffraction pattern. Thus, the technique relies on gathering data from tens of thousands of crystals in random orientations and then stitching the data back together to create integrated diffraction data akin to those collected in a conventional single-crystal experiment. An advantage of the technique is its ability to rapidly collect data from microcrystals, with a high signal-to-noise ratio and in a manner essentially free from radiation damage, which limits the resolution and completeness of traditional crystallographic experiments. SFX was essential for determining the crystal structure of the rhodopsin-arrestin complex 38 , but it has also been used to determine several other 7TM receptor structures [91] [92] [93] . The high rate of data collection in this technique also opens the door to ultrafast time-resolved studies that can be used to measure conformational changes and chemical reactions in crystals 94 .
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Activation of heterotrimeric G proteins. As discussed above, activation of heterotrimeric G proteins occurs through the exchange of nucleotides on the Gα subunits, and the two receptors that have provided the most insight into this process are rhodopsin and β 2 AR. In 2008, opsin was shown to adopt what seems to be an active configuration because it exhibits an outward swing of TM5 and TM6 relative to inactive, dark-adapted rhodopsin, leading to an opening of the cytoplasmic pocket 34 . In a follow-up structure, a peptide derived from the C-terminal end of the α5 helix of Gα t , a region that is known to underlie heterotrimeric G protein specificity for receptors 44 , was shown to bind in the open cytoplasmic pocket 35 (FIG. 2b) .
Later, the structure was re-determined in the presence of all-trans-retinal, reconstituting what was described as an agonist-activated receptor bound to a G protein surrogate 45 . However, these structures all utilized opsin that was crystallized in the same way, and thus crystal lattice contacts may limit conformational changes that could further distinguish among the three structures. A further complication is that if one models a Gαβγ hetero trimer bound to the opsin-Gα t peptide structure by overlaying the C terminus of Gα with the peptide, the resulting heterotrimeric G protein would collide with the membrane surface 46 , suggesting that additional conformational changes occur when a 7TM receptor interacts with an intact heterotrimeric G protein.
In 2011, a consortium of laboratories reported the first such structure: the β 2 AR bound to a nucleotide-free G s heterotrimer 37 . The structural determination required a high-affinity 'super' agonist (BI-167107), an amino-terminal T4 lysozyme fusion of a C-terminally truncated β 2 AR, novel detergents and a cameloid antibody fragment known as nanobody 35 (Nb35; isolated from a llama immunized with a β 2 AR-G s complex stabilized via crosslinking with bis(sulfosuccinimidyl) , blue). In each overlay, the darker colour corresponds to an active, agonist-bound form of the receptor, whereas the lighter colour corresponds to an inactive form. Part a illustrates the extracellular pockets bound to various ligands (ball and stick models, with carbons coloured the same as their receptor). Amino termini and the second extracellular loop (the loop connecting transmembrane strand 4 (TM4) and TM5) were removed when necessary for clarity. Photoactivation or the binding of ligands leads to relatively subtle and inconsistent changes in the helices and loops that form the extracellular pocket (rhodopsin expands, β 2 AR is relatively unchanged, and the μ-opioid and M2 receptors contract). LY2119620 (ball and stick model with pink carbons; see muscarinic receptor) is a positive allosteric modulator that binds to the 'vestibule' of the M2 muscarinic receptor formed by the three extracellular loops of the receptor, and thereby increases the effective affinity of the agonist iperoxo. Receptor activation promotes more dramatic yet consistent changes in the cytoplasmic pockets (illustrated in part b), where the end of TM6 swings away from the core of the transmembrane domain (long arrows), and TM7 and the α8 helix tend to push inward (short arrows), except in the case of rhodopsin. This transition creates a binding site for cytoplasmic proteins, as represented by the transducin peptide bound to opsin 35 (transparent spheres in the cytoplasmic pocket of rhodopsin). 
Ras-like domain
The nucleotide-binding domain of heterotrimeric G protein α-subunits, which also contains binding sites for seven transmembrane (7TM) receptors, Gβγ subunits, and downstream effector enzymes. It contains three switch regions that are conformationally responsive to the identity of the bound nucleotide.
glutarate). Comparison with inactive β 2 AR structures revealed a conformational transition in the cytoplasmic pocket, analogous to that of opsin described above 25, 47 ( FIG. 2) . The structure also revealed that the nucleotidefree, receptor-bound Gα subunit adopts an unusual configuration relative to all previously reported structures of Gα, with its α-helical domain swung more than 130˚ away from the Ras-like domain, and with a markedly rearranged α5 helix at the C terminus of the Raslike domain that docks into the cytoplasmic pocket of the receptor (FIG. 3a,b) . Which of these differences, then, is responsible for receptor-mediated nucleotide exchange? In an accompanying study, single-particle electron microscopy studies (BOX 4) of the complex showed that the α-helical domain is in fact highly mobile when nucleotide-free heterotrimers are bound to β 2 AR 48 (FIG. 3a) , indicating that the α-helical domain in the β 2 AR complex structure is trapped in its unusual configuration by strong crystal contacts mediated by Nb35. Regardless, both studies suggest that exposure of the nucleotide-binding site on Gα to solvent could be an important component of receptor-mediated nucleotide exchange.
In another accompanying study, deuterium exchange mass spectrometry (DXMS) (BOX 3) was used to map which regions of Gα s change their solvent accessibility and/or dynamics when bound to β 2 AR, this time in the absence of Nb35 (REF. 49 ). The results were mostly consistent with those predicted by the crystal structure, except that it was found that regions of Gα that contribute to the nucleotide-binding pocket are highly mobile, as one might expect if both GDP ligand and nanobody were dissociated from the α-subunit. Surprisingly, a central (β1) strand in the Ras-like domain of Gα also exhibited higher mobility. On the basis of this result and the crystal structure of the complex, it was proposed that binding to β 2 AR reorganizes the C-terminal α5 helix and destabilizes the structure of the internal β1 strand of Gα s . As these elements are structurally tethered to bound nucleotides (to the base and phosphates, respectively (FIG. 3a) ), these conformational changes would explain loss of affinity for guanine nucleotides.
Recently, state-of-the-art molecular dynamics simulations were used to further elucidate the nucleotide exchange mechanism
. Simulations of up to 50 μs 
Deuterium exchange mass spectrometry (DXMS)
In DXMS, also known as hydrogen-deuterium exchange (HDX), a receptor complex is placed in D 2 O and, over time, amide hydrogens in the peptide backbone of the complex exchange with deuterium. Amides in less solvent-exposed regions, such as in the hydrophobic core of the protein or in protein-protein interfaces, exchange more slowly than those in more dynamic regions of the protein. Thus, the experiment can be used to map which regions of a protein experience a change in solvent exposure and/or dynamics as a consequence of signalling events and/or complex formation. Data are collected at various times by acidifying the protein sample to quench further exchange, followed by proteolysis with an acid-stable protease. Tandem mass spectrometry is then used to identify the sequence and degree of deuteration of each proteolytic fragment. The resolution of a DXMS experiment is, however, limited by the size of the peptides generated and by the number of peptide fragments that can be identified by the spectrometer. For example, in a DXMS study of the β 2 -adrenergic receptor (β 2 AR)-G s complex, peptides from strands adjacent to β1 in the Ras-like domain of Gα were not observed and thus could not be used to directly confirm the unexpectedly high mobility of this internal strand 49 (FIG. 3a) .
Double electron-electron resonance (DEER) distance measurements
DEER provides information on the distances between paramagnetic centres (chemical moieties with unpaired electrons) in a protein and their relative orientations 95 . Samples are first frozen in vitrified ice, thus emulating a solution environment, and although there is no size limit on the macromolecular assembly, the centres typically need to be 20-60 Å apart from each other for their interaction to be measured. Because most proteins lack such centres, nitroxide groups are installed at discrete locations by chemical modification of specific Cys side chains. This requires the creation of mutant proteins with only one or two reactive Cys side chains per protein complex, in a process called site-directed spin labelling (SDSL). If a nitroxide modification is introduced at a specific position in a receptor such as rhodopsin, and another in a cytoplasmic target such as arrestin, then DEER can be used to estimate the distance between their nitroxide groups in the resulting complex 38 . If enough unique pairs of SDSLs can be analysed, a low-resolution model of the complex can be assembled, provided the structure of each protein is known. DEER is also useful for monitoring allosteric changes within a protein. For example, DEER successfully predicted a receptor-induced rigid-body change in the α5 helix of Gα (FIG. 3a) , years before the crystal structure of a receptor-Gα complex was known 52 .
Nuclear magnetic resonance (NMR)
Unlike DXMS, NMR can assess the dynamics of a protein on a single-residue basis, but it requires isotopic labelling and assignment of peaks in the resulting spectra to specific amino acids, and it generally requires proteins of relatively low molecular weight (typically <40 kDa). The technique was recently used with striking success to determine allosteric mechanisms of activation based on >20 backbone positions in a . Although such labels generate a more limited number of peaks, they can still report on distinct conformations adopted by various receptor-ligand complexes, and their spectra are typically easier to interpret. revealed spontaneous opening of the nucleotidebinding pocket of Gα s , even in the absence of receptor 50 , which is not surprising given that Gα subunits can readily exchange nucleotides in solution 51 . Although this opening was necessary, it was not sufficient for nucleotide release in the simulations. Instead, the movement of the α5 helix -which, as discussed above, undergoes a rigid-body rotation in the Ras-like domain of Gα s when it docks with the receptor (FIG. 3b) -seems to be the key conformational change. The results suggest a model for receptor-mediated nucleotide exchange on G s , wherein the receptor pulls and rotates the α5 helix, thereby perturbing the guanine ring-binding site. This transition is expected to weaken the affinity of Gα s for the bound nucleotide and, in combination with dislodging the α-helical domain from the Ras-like domain, facilitates nucleotide exchange (FIG. 3a) . A similar mechanism was also proposed for rhodopsin on the basis of energetic analysis and site-directed spin labelling (SDSL)-double electron-electron resonance (DEER) distance measure ments 52, 53 
. The role of the β1 strand of the Ras-like domain in nucleotide exchange, as of now, remains unclear.
However, this is unlikely to be the full story. Simulations, even atomistic ones, are at best lowresolution techniques, because they are often difficult to confirm experimentally and can seldom be run over timescales long enough to sample major conformational change. They are also reliant on high-resolution crystal structures, which, as noted above, have their own limitations. NMR, however, is well adapted to study the structure and dynamics of nucleotide-free Gα subunits in solution
. In well-folded proteins, NMR 15 N-1 H heteronuclear single quantum coherence spectra give well-dispersed, sharp peaks corresponding to all backbone and side-chain amide protons. However, the spectra from a nucleotide-free 15 N-labelled Gα bound to activated rhodopsin suggested extensive conformational heterogeneity 54 ; in other words, receptor-bound Gα subunits are very dynamic. The same conclusion was reached for the nucleotide-free inhibitory Gα subunit (Gα i ) bound to Ric8A (also known as synembryn A), a soluble protein that, like 7TM receptors, promotes nucleotide exchange on some classes of Gα subunits in the absence of Gβγ 55 . Interestingly, Ric8A is also thought to interact primarily with the α5 helix of Gα, implying a common mechanism for nucleotide release. These results could be interpreted as a direct consequence of dissociation of a stabilizing ligand (in this case, a guanine nucleotide) but do not exclude the possibility that receptor-mediated disruption of the fold of the Ras-like domain is a part of the nucleotide exchange process.
Activation of arrestins.
Of the four arrestins found in humans, two are primarily expressed in visual neurons (arrestins 1 and 4), and the other two (arrestins 2 and 3; also known as β-arrestins 1 and 2) are ubiquitously expressed and thus responsible for uncoupling G proteins from hundreds of different 7TM receptors. Two independent structural cues can be used by arrestins for recruitment to activated receptors. The first is a transmembrane domain in its active conformation, and the second is a cluster of phosphorylated residues on the cytoplasmic loops or tails of the receptors, typically introduced by a GRK (BOX 1; FIG. 3c) . Which localization cue has a dominant role seems to vary from receptor to receptor, but use of both can be synergistic 56 . Negative stain single-particle electron microscopy analysis (BOX 4) of a chimaera between β 2 AR and the vasopressin receptor in complex with arrestin 2 revealed two distinct regions of the receptor involved in the interaction: the phosphorylated C-terminal tail of the receptor, serving as the dominant site; and the transmembrane core of the receptor (which became more prominently bound by the arrestin after treatment with a chemical crosslinker). The latter structure was supported by DXMS studies
, which revealed loss of mobility in the regions of arrestin that were expected to interact with the transmembrane core of the receptor (see below) 57 . In a subsequent electron microscopy study, the complex between a constitutively active mutant of opsin and a 'pre-activated' variant of arrestin 1 (having three point mutations that induce its active conformation) only yielded reconstructions with the trans membrane core-bound configuration 38 , probably because the receptor used in this study was not phosphorylated.
How does arrestin interact with the transmembrane domain of the receptor? Arrestin is composed of two immunoglobulin-like domains, referred to as the N and C domains (BOX 1; FIG. 3c,d ). Biophysical measurements showed that a so-called 'finger loop' in the N domain becomes immobilized upon receptor binding 58 , consistent with other studies indicating that this region undergoes a major conformational change upon formation of the complex 59, 60 . In the crystal structure of opsin in complex with a peptide derived from the arrestin 1 finger loop, this peptide was modelled as binding in the cytoplasmic pocket in a conformation similar to that of the C terminus of Gα 36 (FIG. 3b,d) . However, the crystal form was the same as that used for other opsin structures, and thus this structure may not provide an accurate picture of the rhodopsin-arrestin interaction.
Most recently, the atomic structure of a constitutively active variant of rhodopsin in complex with the pre-activated variant of arrestin 1 was reported 38 . The two proteins were fused with a 15-amino-acid linker to ensure 1:1 stoichiometry and facilitate crystallization. The structure determination was challenging because of the extraordinarily small size of the crystals (~10 μm) and their poor diffraction behaviour. To get around this, the authors turned to serial femtosecond crystallography (SFX) 61, 62 
. Although many amino acid side chains, including those in the opsin-arrestin interface, were not resolved in the final maps, the structure does provide a high-resolution electron density envelope for a 7TM receptor-arrestin complex, consistent with those from electron microscopy single-particle reconstructions, that can be used as a starting point for modelling interactions with other signalling partners 63 . The crystal structure was further validated by DXMS, crosslinking and DEER distance measurements
.
As expected, the model revealed that the finger loop of arrestin 1 is inserted into the cytoplasmic pocket of the activated receptor, but its conformation was different from that modelled for the peptide in the opsinfinger loop peptide complex 36 (FIG. 3d) . Unfortunately, unbiased electron density maps for the finger loops in both of these crystal structures are relatively featureless, rendering modelling difficult. The consistently poor quality of the finger loop density in these structures may, however, indicate that the loop can adopt multiple configurations within the cytoplasmic pocket of the receptor. This protean quality may underlie the ability of arrestin to recognize the activated conformation of hundreds of different 7TM receptors. Whereas exposed loops of the N domain of arrestin 1 underlie the bulk of the interactions with rhodopsin, the C domain is rotated upwards 20˚ relative to that of inactive arrestin 1 (REF. 64 ), such that it could interact with the membrane surface through the hydrophobic residues presented at the tip of the C domain (FIG. 3d,e) . This would be consistent with the existence of a potential phosphoinositide ▶ head group-binding site previously observed in the C domain of arrestin 2 (REF. 65 ) and would further support the idea that some arrestins, like heterotrimeric G proteins, require coordinate interactions with both receptor and membrane for full activity 66 .
Interactions of arrestins with phosphorylated receptor peptides have also been investigated. The crystal structure of an antibody-stabilized complex between an octa-phosphorylated peptide derived from the C terminus of the vasopressin receptor and C-terminally truncated arrestin 2 showed how phosphorylated residues interact with basic residues in the N domain (FIG. 3f) . These interactions seem to disrupt the polar core of arrestin 2, thereby inducing a conformational change between its N and C domains and reorganizing exposed loops that could then interact with receptors 67 . Caveats from this experiment concern the extent of phosphorylation of the peptide (because it is unclear how many sites need to be phosphorylated for arrestin to functionally interact with receptors in vivo 68 ) , and the fact that the antibody interacts with both arrestin and the phosphopeptide and thus may be, in part, responsible for the observed arrestin conformation. However, the N and C lobes of arrestin 2 in this complex superimpose well with those of the pre-activated variant of arrestin 1 in complex with rhodopsin 38 (FIG. 3d) .
Taken together, these studies support a model wherein the binding of arrestin to phosphorylated sites on 7TM receptors disrupts the interaction of its C-terminal tail with its N-terminal strand and helix I in the N domain (the so-called three-element inter action 69 ), thereby allowing the N and C domains to reorganize and create binding sites for other signalling molecules 63 , as well as the transmembrane core of the receptor. Multivalent interactions between arrestin and the receptor help to increase their affinity and thereby more effectively block heterotrimeric proteins from the receptor. In the case of arrestins 2 and 3, the released C-terminal tail has binding sites for the endocytic machinery 70, 71 , which targets the complex for internalization and instigates other signalling events
Activation of GRKs.
Less well understood is the molecu lar basis for how GRKs interact with 7TM receptors. These complexes present additional challenges, owing to the larger size of GRKs relative to arrestins, their conformational flexibility, their low affinity for activated receptors and their requirement for phospho lipids for full activity. There are no known constitutively active mutants of GRKs that could be exploited to gain insight into receptor-mediated activation mechanisms. The available studies suggest that GRKs target activated receptors via an intrinsically disordered N terminus that becomes helical when it encounters an activated receptor -or, alternatively, an appropriate lipid environ ment, because lipids can activate GRK phosphorylation of non-receptor targets [72] [73] [74] . This helical region is predicted to form a bridge between the cytoplasmic pocket of the receptor and the GRK that concomitantly stabil izes a catalytically competent configuration of the kinase domain 73 . As in the C termini of Gα subunits and the finger loops of arrestins, the extreme N terminus of GRKs contains conserved acidic and hydrophobic resid ues that complement the general surface properties of the cytoplasmic pocket in activated 7TM receptors.
Conclusions and outlook
The available structural data have revealed that the process by which 7TM receptors transfer signals to heterotrimeric G proteins, GRKs and arrestins is analogous to thumbing a ride. In their receptor-interacting conformations, Gα subunits rotate and extend their C-terminal α5 helix, arrestins reorient a centrally project ing finger loop and GRKs offer an N-terminal helix. In each case, the extended structure is accompanied by an activating conformational change of the cytoplasmic partner, which is stabilized not only by the receptors, but also by interactions with the surrounding phospholipid bilayer
. Successful 'hitchhiking' seems to involve common principles: an open cyto plasmic 'door' on the 7TM receptor (achieved by receptor activation); a patch of negatively charged membrane surrounding the receptor; and physicochemical comple mentarity of the extended 'thumb' with the cytoplasmic pocket of the receptor. Such is . Arrows represent the β-strands that form the core sheet of the Ras-like domain. The β1 strand, which precedes the P-loop that binds to phosphate moieties of guanine nucleotides (circles marked with 'P'), has also been reported to become more solvent accessible in the nucleotidefree state 49 . The termini of Gα are marked N and C. b |The C-terminal α5 helix in the Ras-like domain of Gα s adopts a markedly different position in the receptor bound conformation (PDB entry 3SN6 (REF. 37 ), firebrick) as compared to its conformation in its GTP-bound state (PDB entry 1AZT 110 , purple). The side chains of two hydrophobic residues (Leu388 and Tyr391) that make extensive interactions with transmembrane strands TM3, TM5 and TM6 of the receptor (in this case β 2 AR) are shown as sticks to emphasize the change in the position of α5 helix. c | Schematic of the interactions of arrestin with an activated receptor. Most contacts are formed by the N domain, most prominently by the finger loop, which projects into the cytoplasmic pocket. The N domain also forms most of the contacts with phosphorylated residues from the receptor. Together, these interactions help to rearrange the polar core between the N and C domains and release the C terminus of arrestin from the N domain. d | When arrestin binds to an activated receptor, the C domain twists ~20˚ relative to the N domain, and the conformation of the finger loop (magenta) is altered so that it can directly interact with the transmembrane domains of 7TM receptors (PDB entry 4ZWJ 38 ). e | Inactive structure of arrestin 1 (PDB entry 1CF1 (REF. 64)). Its C terminus (yellow) binds to the N domain, thereby blocking interactions with MAP kinases and the endocytic machinery. f | Arrestins also bind to the phosphorylated C-terminal tails of 7TM receptors, as exemplified here by the arrestin 2-vasopressin phosphopeptide complex (PDB entry 4JQI 67 ). Phosphates are depicted as orange spheres. Note that the C-terminal end of the vasopressin peptide would displace the C terminus of arrestin shown in part e, indicating that this interaction can activate the signalling function of arrestins by unblocking sites on the N domain responsible for interactions with other cellular components. It remains to be determined which of the 'activated' finger loop models shown are physiologically relevant. The conformation observed in 4JQI could, however, reflect how arrestin 2 binds to a phosphorylated C-terminal tail when it is not also engaged with the transmembrane domain of a 7TM receptor.
consistent with the central metaphor of this Review: like hitchhikers, who accept rides from diverse vehicles, heterotrimeric G proteins, GRKs and arrestins have to take advantage of general features of an activated 7TM receptor rather than specific contacts.
Similarities in the interactions of 7TM receptors with their intracellular partners extend beyond the 'thumb' . Whereas DXMS indicates that the receptor-interacting regions of Gα subunits and arrestins become more ordered upon complex formation 38, 49 , both NMR and DXMS indicate that the rest of their domains become more dynamic 49, 54, 57, 75 . In other words, free energy gained by complex formation is used to leverage energetically unfavourable structural changes that are necessary for signal propagation, such as ejection of the guanine nucleotide from Gα or reorganization of the N and C domains of arrestin. Interestingly, the current structural models suggest that heterotrimeric G proteins and arrestins emphasize different contacts with 7TM receptors in and around the cytoplasmic pocket. By preferentially perturbing receptor contacts important for one cytoplasmic partner over another, biased agonists can thus elicit distinct cellular responses.
Not covered in this Review, but of possible importance for some 7TM receptors, is the prospect of regulating signalling through oligomerization (glutamate family 7TM receptors are already constitutive dimers via interaction of their extracellular domains; see FIG. 1 ), which could influence their ligand-stabilized conformations and how they interact with cytoplasmic partners. Although parallel (hence physiologically reasonable) packing interactions have been observed between transmembrane helical bundles in some crystal structures of 7TM receptors thought to be dimeric in vivo 76 , it is not yet clear whether these lattice contacts are functionally relevant or simply represent fortuitous crystal packing. Current in vitro evidence seems to disfavour the idea of dimerization as a general feature of 7TM receptors that contributes to their interactions with cytoplasmic targets: when constrained to be monomeric in artificial nanodisc particles, 7TM receptors are fully functional with respect to G protein coupling [77] [78] [79] , GRK phosphorylation 80, 81 and arrestin binding 80, 82 . There are also some overarching general conclusions regarding the structural analyses of 7TM receptor complexes. Membrane proteins are already challenging targets for structural studies, and complexes between 7TM receptors and their signalling partners add an additional layer of difficulty, because they are often transient and involve various conformational transitions as part of their function. It is notable, and not accidental, that the β 2 AR-G s and rhodopsin-arrestin crystal structures were extensively supplemented by companion studies, including electron microscopy, DXMS, DEER and molecular dynamics (BOXES 3, 4) . This, at first glance, may suggest that the approaches used to generate these atomic models impose enough caveats that other methods are required for validation. Alternatively, it may simply reflect the fact that crystal structures on their own are just snapshots -very important ones, but snapshots nevertheless -and as such, they could never provide a full molecular description of a dynamic biological process. Big structural problems, such as receptor-G protein or receptorarrestin complexes, require networks of complementary expertise that are rarely found in a single laboratory.
There remains an immense need for additional structures of 7TM receptors in complex with their cytoplasmic signalling partners. Additional structures are expected to provide further insights into which specific interactions are important for selectivity (for example, how receptors determine which Gα subunits they couple with) and for biased signalling. In addition, the different ways in which various laboratories tackle these complex problems tend to eliminate artefacts resulting from any specific experimental approach. Determining these important structures will require not only great fortitude but also funding for projects that are long-term, high-risk and highly collaborative endeavours. However, the potential payoffs are huge, as these structural studies contribute immensely to our understanding of the molecular mechanisms underlying cellular responses to extracellular stimuli, thereby opening up new prospects for controlling cellular physiology and treating numerous diseases.
Box 4 | Other complementary structural techniques
Molecular dynamics
Detailed information on processes including ligand binding and conformational change, such as nucleotide exchange on Gα, cannot be obtained from static crystal structures. Direct measurement of these events is also beyond the range of most experimental techniques because they occur on microsecond timescales. However, crystallographic models do provide a framework for computational simulations that can generate novel hypotheses about these physiologically important processes. In these in silico experiments, atoms of a protein model are allowed to interact with each other and with solvent molecules after some kinetic energy is added to the system, and the resulting trajectories are analysed to learn about protein or ligand-binding behaviour. Recently, specialized microprocessors engineered specifically for molecular dynamics, and new physical models for interatomic interactions have extended the range of these computations by orders of magnitude so that they can sample microsecond timescales 102 . For example, simulations were used to monitor the binding and release of tiotropium to muscarinic acetylcholine receptors and provided evidence for the presence of an allosteric ligand-binding site in the 'vestibule' of the receptor 103 ( see FIG. 2a , right).
Single-particle electron microscopy reconstructions
Recent technological advances, such as the direct electron detector, have enabled ever-higher-resolution three-dimensional single-particle reconstructions of samples imaged by electron microscopy 104 . Small targets (<200 kDa) are usually imaged by staining with chemicals such as uranyl acetate, which improves contrast. Ideally, however, samples are embedded in vitreous ice for a cryo-electron microscopy study, thereby preserving them in a more native environment. In this technique, tens of thousands of individual measured projections of the particles are aligned and then integrated into a consistent three-dimensional structure. Asymmetric protein assemblies are better candidates for this approach than globular ones, because they allow more accurate alignment. Different conformational states present in a single sample can also be differentiated and independently reconstructed. Recently, the structure of a 500 kDa enzyme 105 , as well as membrane proteins such as the 400 kDa TrpV1 channel 106 , were reported at 3-4 Å resolution, which was sufficient to trace the backbone, model side chains and identify ligand-binding sites. Thus, single-particle electron microscopy is increasingly viewed as an alternative technique to X-ray crystallography. In practice, however, crystallographic models are still required for validation of electron microscopy-derived data, as in the case of single-particle electron microscopy reconstructions of receptor-heterotrimeric G protein 48, 107 and receptor-arrestin 38, 57 complexes.
